Ctdna Monitoring in Predicting Relapse of Primary Mediastinal B-Cell Lymphoma

医学 单变量分析 纪元(天文学) 阶段(地层学) 肿瘤科 胃肠病学 内科学 多元分析 淋巴瘤 生物 天文 物理 星星 古生物学
作者
Diwen Pang,Xinmiao Jiang,Ling Huang,Yan Teng,Sichu Liu,Feili Chen,Xiaojuan Wei,Hanguo Guo,Wenyu Li
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 36-36 被引量:2
标识
DOI:10.1182/blood-2020-142349
摘要

Background: Primary mediastinal B-cell lymphoma (PMBCL) is a rare subtype of aggressive B-cell lymphoma. The majority of relapses occur within the first few months resulting in a dismal prognosis, thus we need to identify the risk of early relapse. Circulating tumor DNA (ctDNA)-based response assessment may enable response adapted therapy and early prognostication. In this study, we aim to clarify the role of ctDNA-monitoring in early prediction of relapse. Methods: We retrospectively analyzed the characteristics of 38 patients with PMBCL. The genetic sequencing and ctDNA monitoring were conducted by target next-generation sequencing (NGS). Results: The median age was 32 years old and 26 (68.4%) were female. Most cases (31/38, 81.6%) were diagnosed with stage I or II disease and fourteen (36.8%) cases present with extranodal involvement. The 5-year PFS and OS for PMBCL patients were 65.7 and 72.1%, respectively. High IPI score were associated with poor survival by univariate analysis. The complete response (CR) rate and overall response rate of R-CHOP was similar to R-EPOCH (69.2% vs. 70.0%, P =1.000 and 84.6% vs. 95.0%, P =0.547, respectively), however the 5-year PFS and OS rate for R-EPOCH seems longer than those for the R-CHOP (PFS 82.9% vs. 53.8%, P=0.0569; OS 92.9% vs. 60.6%, P=0.0567). Radiotherapy was less delivered in the patients who received R-EPOCH than R-CHOP (5.0% vs.53.8%, P=0.003) and had no impact on prognosis. We performed genetic sequencing on twenty-three cases. STAT6(15/23, 65.2%), SOCS1(13/23, 56.5%), TNFAIP3(13/23, 56.5%) were the most common affected genes in both response and refractory/relapsed patients. Cell cycle, FoxO signaling pathway and TNF signaling pathway were more frequently involved in refractory patients. ctDNA monitoring was conducted in 16 cases and fifteen cases show undetectable ctDNA after a median of 2 (range from 1 to 5) cycles and one refractory case presented with durable positive ctDNA. Among 4 relapse cases, 3 had prior detectable ctDNA half a month earlier before imaging manifestations of relapse. Regarding prediction of relapse, positive predictive value of ctDNA is 100%. Conclusions: Intensive induction chemotherapy can improve prognosis of PMBCL and ctDNA precisely predicted relapse. As most cases relapse within a few months, ctDNA-monitoring is crucial to improve prognosis. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
清脆的人生完成签到,获得积分20
刚刚
2秒前
3秒前
pep发布了新的文献求助10
3秒前
Aurora.H发布了新的文献求助10
4秒前
5秒前
Jasper应助清脆的人生采纳,获得10
6秒前
彩色的恋风完成签到,获得积分10
6秒前
李健的小迷弟应助梁洛嘉采纳,获得10
7秒前
和敬清寂发布了新的文献求助10
7秒前
等待的大炮完成签到,获得积分10
8秒前
星辰大海应助solitude采纳,获得10
8秒前
hvivi6发布了新的文献求助10
10秒前
10秒前
11秒前
尼美舒利完成签到 ,获得积分10
11秒前
研友_n2Bkrn完成签到,获得积分10
11秒前
11秒前
12秒前
Bourne完成签到,获得积分20
12秒前
zzzqqq完成签到,获得积分10
13秒前
burn发布了新的文献求助10
14秒前
Bourne发布了新的文献求助10
15秒前
ElbingX发布了新的文献求助20
16秒前
16秒前
16秒前
Zz发布了新的文献求助10
16秒前
笑靥如花发布了新的文献求助10
16秒前
董晓坤完成签到,获得积分10
18秒前
彭于晏应助hvivi6采纳,获得10
18秒前
19秒前
20秒前
yyyyyy完成签到 ,获得积分10
20秒前
21秒前
貔貅完成签到,获得积分10
21秒前
DD立芬完成签到 ,获得积分10
22秒前
23秒前
23秒前
敬老院N号应助南宫映榕采纳,获得30
23秒前
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976177
求助须知:如何正确求助?哪些是违规求助? 3520366
关于积分的说明 11202745
捐赠科研通 3256847
什么是DOI,文献DOI怎么找? 1798509
邀请新用户注册赠送积分活动 877704
科研通“疑难数据库(出版商)”最低求助积分说明 806516